Which Adverse Effects Influence the Dropout Rate in Selective Serotonin Reuptake Inhibitor (Ssri) Treatment?

Kostev, Karel; Ehlken, B; Rex, Juliana; Engelhard, J.; Altmann, Vivian; Heilmaier, Christina

doi:10.1016/j.jval.2014.08.1272

Cited by 22 publications

(26 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another possibility for this high dropout rate could be the potential side effects that arose from the intervention. This has been already shown extensively in the literature, in which increased dropout rate in drug trials is significantly associated with adverse effect severity [19,20]. This could certainly be the case in this study, as participants with SCI submitted to verum stimulation reported significant more skin redness, sleepiness, scalp pain, scalp burning sensation, and tingling as compared to those receiving the placebo.…”

Section: Discussionsupporting

confidence: 72%

Study adherence in a tDCS longitudinal clinical trial with people with spinal cord injury

et al. 2017

View full text Add to dashboard Cite

Despite all the measures to improve study adherence (such as providing parking, flexibility to schedule sessions, follow-up with participants by phone), it seems that long follow-up periods may increase the likelihood of dropout. Given the need to understand long-term effects of interventions, longitudinal trials need to consider alternative designs or methods of treatment (for instance home treatment or home assessment) to decrease attrition rate.

show abstract

Section: Discussionsupporting

confidence: 72%

Study adherence in a tDCS longitudinal clinical trial with people with spinal cord injury

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Selective Serotonin Receptor Inhibitors (SSRIs) are the most commonly prescribed antidepressants with a prevalence of use in adults of 4%‐8.5% depending on geographical location . Although treatment with SSRIs is generally well tolerated, a recent meta‐analysis found that treatment with SSRIs was associated with a 1.55‐fold increase in the risk of developing upper gastrointestinal bleeding compared to patients who had not taken SSRIs . The risk of developing upper gastrointestinal bleeding was particularly increased in patients taking concurrent nonsteroidal anti‐inflammatory drugs (NSAIDs; odds ratio [OR]: 3.72), or concurrent antiplatelet drugs (OR: 2.48) .…”

Section: Introductionmentioning

confidence: 99%

The use of selective serotonin receptor inhibitors (SSRIs) is not associated with increased risk of endoscopy‐refractory bleeding, rebleeding or mortality in peptic ulcer bleeding

Laursen

Leontiadis

Stanley

et al. 2017

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…29,30,35 . In this way, we can see that since these drugs act on the central nervous system, they produce lots of effects on the organism, and therefore, they are among the treatments that generate more ADR in our study.…”

Section: Discussionmentioning

confidence: 99%

Treatments that generate higher number of adverse drug reactions and their symptoms

Fernandez-Lopez¹,

Navarro‐Zaragoza

Falcón³

et al. 2015

Ars Pharm

View full text Add to dashboard Cite

LICENSE 3.0 UNPORTED. RESUMENIntroducción. Las Reacciones Adversas a Medicamentos (RAM) constituyen una importante fuente de morbilidad y mortalidad en todo el mundo, generando altos costes económicos. Por ello, el objetivo de este estudio fue determinar aquellos tratamientos que producen una mayor cantidad de RAM en la población general así como conocer los principales síntomas que generan. Material y métodos.Se realizó un estudio transversal observacional mediante la cumplimentación de un cuestionario. Para ello, 510 pacientes fueron encuestados sobre qué patologías tenían diagnosticadas, sus tratamientos farmacológicos y las RAM sufridas.Resultados. Un 26,7% de los pacientes encuestados había sufrido alguna RAM. Obtuvimos resultados estadísticamente significativos (p ≤ 0.05) al clasificar a los pacientes según el tratamiento prescrito y el número de RAM sufridas para los tratamientos farmacológicos de artrosis, anemia y enfermedades del sistema nervioso (ansiedad, depresión, insomnio). Además cuantificamos frecuencias de aparición de RAM mayores en aquellos fármacos prescritos contra la artrosis (22,6% de los casos sufrieron RAM), anemia (14,28%), alteraciones nerviosas (13,44%) y asma (16%). En cuanto a los síntomas producidos, los más frecuentes fueron gastrointestinales (60% de los pacientes) y alteraciones nerviosas (mareos, dolor de cabeza, problemas de conciliación del sueño etc, 24,6%).Discusión. La principal conclusión de nuestro estudio es que aquellos fármacos que producen mayor número de RAM están prescritos para el tratamiento de la artrosis, la anemia, las alteraciones nerviosas y el asma. Además, los síntomas que aparecen principalmente tras una RAM son alteraciones gastrointestinales y nerviosas. Los profesionales sanitarios deberían estar alerta ante la posible aparición de RAM en dichos tratamientos y proporcionar a sus pacientes el empoderamiento necesario para que ellos mismos pudieran detectarse RAM. Esto evitaría consecuencias negativas tanto en su estado de salud como en el gasto sanitario.Palabras clave: reacciones adversas, farmacoterapia, síntomas, frecuencia, enfermedad crónica. ABSTRACTObjectives. Adverse drug reactions (ADRs) are an important cause of morbidity and mortality worldwide and generate high health costs. Therefore, the aims of this study were to determine the treatments which produce more ADRs in general population and the main symptoms they generate.Methods. An observational, cross-sectional study consisting in performing a self-rated questionnaire was carried out. 510 patients were asked about the treatments, illnesses and ADRs, they had suffered from.Results. 26.7% of patients had suffered from some ADR. Classifying patients according to the type of prescribed treatment and studying the number of ADR that they had, we obtained significant differences (p ≤ 0.05) for treatments against arthrosis, anemia and nervous disorders (anxiety, depression, insomnia). Moreover, determining absolute frequencies of these ADRs appearance in each treatment, higher frequencies were ag...

show abstract

Which Adverse Effects Influence the Dropout Rate in Selective Serotonin Reuptake Inhibitor (Ssri) Treatment?

Abstract: in terms of longer length of stay, more readmissions and higher consumption of drugs. The average quality of the studies was moderate. Further research is needed to establish the degree of burden of agitation and containment borne by hospitals and the health care system.

Cited by 22 publications

References 0 publications

Study adherence in a tDCS longitudinal clinical trial with people with spinal cord injury

Study adherence in a tDCS longitudinal clinical trial with people with spinal cord injury

The use of selective serotonin receptor inhibitors (SSRIs) is not associated with increased risk of endoscopy‐refractory bleeding, rebleeding or mortality in peptic ulcer bleeding

Treatments that generate higher number of adverse drug reactions and their symptoms

Contact Info

Product

Resources

About